Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rifaximin SSD

Small molecule · developed by Bausch Health Americas

Phase 3 Most advanced trial
BHC Developer
2 Registered trials

What is Rifaximin SSD?

Rifaximin SSD is a solid soluble dispersion formulation of rifaximin, studied as an immediate-release twice-daily product.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Gastroenterology, Neurology
Developer
Bausch Health Americas, Inc. (BHC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05071716 Phase 3 Hepatic Encephalopathy Completed BHC
NCT06718686 Phase 1/2 Dementia Alzheimer Type Recruiting BHC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dementia Alzheimer TypeDementia Associated With Cerebrovascular DiseaseHepatic Encephalopathy

More from Bausch Health Americas

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the BHC page.

Follow BHC, the company behind Rifaximin SSD

See BHC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.